Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia
PHASE3CompletedINTERVENTIONAL
Enrollment
29
Participants
Timeline
Start Date
March 31, 2007
Conditions
Diabetes Mellitus, Type 2Dyslipidemia
Interventions
DRUG
Fenofibrate 80 mg and metformin 1000 mg (fixed combination)
Trial Locations (3)
Unknown
Site 3, Marseille
Site 1, Nantes
Site 2, Tours
All Listed Sponsors
lead
Solvay Pharmaceuticals
INDUSTRY
NCT00490178 - Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia | Biotech Hunter | Biotech Hunter